RollingStone Co

RollingStone Co Current Liabilities

The Current Liabilities of RollingStone Co (214610.KQ) as of Oct 22, 2026 is 35.24 M KRW. In the previous year, Current Liabilities was 9.84 B KRW — a change of -99.64% (lower).

Current Liabilities

35.24 MKRW

YoY

-99.64%

Last updated:

Current Liabilities of RollingStone Co is 2025 35.24 M KRW. Current Liabilities of RollingStone Co was 2024 9.84 B KRW. It decreases by -99.64% lower compared to the previous year.

The RollingStone Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
1.14 B KRW
Jan 1, 2019
18.38 B KRW
Jan 1, 2020
8.87 B KRW
Jan 1, 2021
11.72 B KRW
Jan 1, 2022
18.04 B KRW
Jan 1, 2023
10.25 B KRW
Jan 1, 2024
9.84 B KRW
Jan 1, 2025
35.24 M KRW
The RollingStone Co Current Liabilities history
YEARCurrent LiabilitiesYoY
35.24 MKRW-99.64%
9.84 BKRW-4.03%
10.25 BKRW-43.18%
18.04 BKRW+53.91%
11.72 BKRW+32.09%
8.87 BKRW-51.71%
18.38 BKRW+1,516.29%
1.14 BKRW-50.02%
2.28 BKRW+163.62%
863.00 MKRW+12.37%
768.00 MKRW-94.36%
13.61 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RollingStone Co Stock analysis

What does RollingStone Co do? MiCo BioMed Co. Ltd. generates revenue through three business segments. The Molecular Diagnosis segment sells nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. The Biochemical Diagnosis segment supplies complex diagnostics, anemia meters, blood glucose meters, medical devices, and strips. The Immunodiagnostic Business segment produces and sells immunodiagnostic devices and immunodiagnostic kits. These products are sold to healthcare providers and medical facilities that require diagnostic tools for patient testing and analysis. The company's products target healthcare institutions including hospitals and clinics. Medical professionals use these devices for accurate diagnosis and treatment planning. The Biochemical Diagnosis segment's blood glucose meters and anemia meters are particularly used in point-of-care testing environments. The Molecular Diagnosis segment's gene amplification equipment supports laboratory-based genetic testing procedures. MiCo BioMed's business model focuses on direct sales to medical institutions and healthcare providers. The company does not mention any third-party distributors or online sales channels. Its product portfolio serves both hospital laboratories and outpatient diagnostic centers. The Immunodiagnostic Business segment's kits are designed for rapid testing applications in clinical settings. RollingStone Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RollingStone Co stock

Current Liabilities of RollingStone Co is 35.24 M KRW in 2025.

Current Liabilities of RollingStone Co changed from 9.84 B KRW to 35.24 M KRW, representing a -99.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities RollingStone Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's RollingStone Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RollingStone Co

All Key Metrics — RollingStone Co